AbbVie (ABBV) 10-K Summary — Year Ended Dec 31, 2024
AbbVie's revenue grew compared to the prior year, while operating income and net income were reported. Operating cash flow remained substantial, though it declined due to working capital timing and higher contingent consideration payments.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
AbbVie's revenue grew compared to the prior year, while operating income and net income were reported. Operating cash flow remained substantial, though it declined due to working capital timing and higher contingent consideration payments.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$56.3B
Revenue reported for the fiscal year.
Operating income
$9.1B
Income from operations reported for the year.
Net income
$4.3B
Net income reported for the year.
Operating cash flow
$18.8B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $56.2B | n/a |
| Dec 31, 2022 | $58.1B | +3.3% |
| Dec 31, 2023 | $54.3B | -6.4% |
| Dec 31, 2024 | $56.3B | +3.7% |
Business overview
The supplied filing sections do not contain a description of the company's business.
Financial performance
Revenue increased compared to the prior year, while operating income and net income were reported. Operating cash flow remained substantial.
Material risks
The filing references risk factors but does not provide specific details in the supplied context.
Liquidity and capital
Operating cash flows declined from the prior year due to working capital timing and higher contingent consideration payments, partly offset by revenue growth. Investing activities reflected significant cash outlays for acquisitions, funded by debt. Financing activities included debt issuance and repayments.
What to watch
Monitor the financial and operational impact of the recent acquisitions of ImmunoGen and Cerevel Therapeutics.